RHPRG4 FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

January 30, 2025

Study Completion Date

February 28, 2025

Conditions
Ocular Graft-versus-host Disease
Interventions
DRUG

rhPRG4

Sterile isotonic aqueous solution containing rhPRG4 (450 µg/mL) for topical administration, 10 mM sodium phosphate, 150 mM sodium chloride \& 0.01% polysorbate 20 at pH 7.2. In all subjects, both eyes will be treated

All Listed Sponsors
collaborator

Lubris, LLC

UNKNOWN

collaborator

Sydney Eye Hospital

UNKNOWN

lead

Lubris Bio Pty Ltd

INDUSTRY

NCT06495307 - RHPRG4 FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD) | Biotech Hunter | Biotech Hunter